Skip to content

    NOCIL

    NOCIL
    Chemicals·12 Feb 2026
    Management Summary

    NOCIL reported a mixed Q3 FY26, with domestic volumes showing high single-digit growth, contributing to a stable quarterly revenue of Rs. 316 crores and an improved operating EBITDA of Rs. 27 crores. However, international markets faced headwinds from seasonal effects and U.S. tariffs, leading to lower price realizations and a sequential decline in PBT and PAT. The company is progressing with its TDQ antioxidant expansion and expects significant volume and margin improvements in the coming years, supported by antidumping measures and new product introductions.

    Highlights

    8
    • Domestic volumes witnessed high single-digit growth in Q3 FY26.

    • Expected FY26 volume growth of 3-4% despite H1 FY26 degrowth of -5%.

    • Q3 FY26 operating EBITDA increased to Rs. 27 crores from Rs. 22 crores in Q2 FY26, representing a 22.7% QoQ growth.

    • Q3 FY26 EBITDA margin stood at 8.5%.

    • TDQ antioxidant investment at Dahej is ahead of schedule, with production trials planned for H1 CY26.

    • NOCIL received the CII Industry Academia Partnership Award 2025 in the diamond category.

    • New products are expected to contribute 10-12% of current volumes.

    • Management expects an annual EBITDA margin improvement of 150 basis points plus or minus over the next 2-4 years.

    Concerns

    5
    • International markets dampened due to seasonal effects and U.S. tariff issues.

    • Lower price realizations influenced by competitive pricing pressures, including dumping from imports.

    • PBT for Q3 FY26 decreased to Rs. 13 crores from Rs. 19 crores in Q2 FY26, a 31.6% QoQ decline.

    • Profit after tax for Q3 FY26 decreased to Rs. 9 crores from Rs. 12 crores in Q2 FY26, a 25% QoQ decline.

    • Antidumping investigations faced administrative delays, pushing conclusions to the next 1.5-2 months.

    Key financials

    Metrics

    10

    Periods

    2

    Headline

    5
    • Revenue
      ₹316 Cr
      QoQ-1.6%
    • Operating EBITDA
      ₹27 Cr
      QoQ+22.7%
    • EBITDA Margin
      8.5%
    • PBT
      ₹13 Cr
      QoQ-31.6%
    • PAT
      ₹9 Cr
      QoQ-25%

    9M

    5
    • FY26 Revenue
      ₹973 Cr
      YoY-7.6%
    • FY26 Operating EBITDA
      ₹80 Cr
      YoY-22.3%
    • FY26 EBITDA Margin
      8.2%
    • FY26 PBT
      ₹55 Cr
      YoY-37.5%
    • FY26 PAT
      ₹39 Cr
      YoY-52.4%

    Capital allocation

    1
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Guidance & targets

    6
    CategoryTargetPriority
    Volume Growth
    Overall FY26 Volume Growth
    3-4%
    High
    Capacity Expansion
    TDQ Antioxidant Production Trials
    H1 CY26
    High
    New Product Contribution
    New Products Volume Contribution
    10-12%
    Medium
    Export Volume Recovery
    U.S. Lost Volumes Recovery
    50%
    Medium
    Margin Improvement
    Annual EBITDA Margin Improvement
    150 basis points plus or minus
    Medium
    Export Volume Growth
    FY26 Export Volume Level
    flat
    High

    Antidumping Duty Investigation Outcome

    Next 1.5-2 months
    CurrentPending, delayed due to administrative restructure
    TargetConclusion of findings

    Why it matters

    Crucial for addressing import dumping and improving price realizations and margins.

    So, we hope that in the next 1.5, 2 months, they should conclude the findings.

    How to verify

    risks_and_concerns[risk='Competitive pricing pressures and dumping from imports']

    Risks & concerns

    4
    RiskSeverity

    Competitive pricing pressures and dumping from imports

    Lower price realizations influenced by competitive pricing pressures, including dumping from imports, leading to antidumping petitions.Management acknowledged

    high

    U.S. tariff issues and seasonal effects impacting international volumes

    Volumes in international markets were dampened due to seasonal effects and U.S. tariff issues, though recovery is expected.Management acknowledged

    medium

    Delays in antidumping investigations

    Antidumping duty findings were delayed due to administrative restructuring, with conclusions now expected in 1.5-2 months.Analyst acknowledged

    medium

    Raw material price volatility

    Increase in key raw material (Aniline) prices, which management expects to pass on.Analyst acknowledged

    medium

    Q&A highlights

    7

    “Going forward, with the tariff situation, surely the India-EU FTA is only expected to come into play in calendar year '27 roughly. But the U.S. tariffs, clearly, we see some of the volumes coming back in a 2- to 3-month horizon; whatever we had kind of lost, we expect that to come back. And with the domestic buoyancy that we see, I would say financial year '27, definitely see growth prospects as well.”

    Management provides a clear outlook on future volume growth drivers, including specific timelines for US volume recovery and EU FTA impact.

    asked by Nirav Jimudia

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance Overview

    NOCIL reported Q3 FY26 revenue of Rs. 316 crores, a slight sequential decline from Rs. 321 crores in Q2 FY26. Operating EBITDA, however, improved to Rs. 27 crores from Rs. 22 crores QoQ, resulting in an EBITDA margin of 8.5%. For the nine months ended December 2025, revenue stood at Rs. 973 crores, down from Rs. 1,053 crores in the prior year, with operating EBITDA at Rs. 80 crores (8.2% margin) compared to Rs. 103 crores.

    02

    Domestic vs. International Market Dynamics

    Domestic volumes showed high single-digit growth in Q3 FY26, driven by improved demand due to GST 2.0. In contrast, international markets experienced dampened volumes due to seasonal effects and U.S. tariff issues, leading to an 8-9% degrowth in export volumes for the nine-month period. Management anticipates a recovery of approximately 50% of lost U.S. volumes within 2-3 months and expects overall FY26 volumes to grow 3-4%, with FY27 showing double-digit growth.

    03

    Antidumping Measures and Trade Agreements

    The company has filed antidumping petitions on select key products to counter competitive pricing pressures and dumping from imports. While findings were delayed due to administrative restructuring, conclusions are now expected within the next 1.5-2 months. NOCIL has also initiated a case against Korean antioxidant products. The India-EU FTA, expected to come into play in calendar year 2027, is anticipated to support strategic engagement in European markets.

    04

    Capacity Expansion and New Product Development

    The TDQ antioxidant investment at Dahej is progressing ahead of schedule, with production trials slated for the first half of calendar year 2026. This expansion, along with new products currently in soft launch, is expected to contribute 10-12% to current volumes, with significant ramp-up anticipated from FY28-29. These initiatives are crucial for future volume growth and market share expansion.

    05

    Cost Optimization Initiatives

    NOCIL has achieved approximately Rs. 23 crores in conversion cost savings over the nine-month period compared to the previous year. These savings stem from conscious efforts to control working capital, align production with inventory adjustments, and efficient management of utilities. The company aims for a sustained annual improvement of 150 basis points in EBITDA margin over the next 2-4 years through ongoing cost initiatives.

    06

    Indian Rubber Chemical Market Overview

    The Indian rubber chemical market is estimated to be around 85,000 tons. NOCIL holds a 40% market share (excluding intermediates) or 60% (including intermediates), indicating a significant opportunity for growth through import substitution and leveraging its expanded capacities. The latex segment currently operates at about 60% capacity utilization, providing headroom for future growth.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.